191 related articles for article (PubMed ID: 9259428)
21. Managed care implications in managing rheumatoid arthritis.
Owens GM
Am J Manag Care; 2014 May; 20(7 Suppl):S145-52. PubMed ID: 25180623
[TBL] [Abstract][Full Text] [Related]
22. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.
Guillemin F; Durieux S; Daurès JP; Lafuma A; Saraux A; Sibilia J; Bourgeois P; Sany J
J Rheumatol; 2004 Jul; 31(7):1297-304. PubMed ID: 15229947
[TBL] [Abstract][Full Text] [Related]
23. Traditional Cardiovascular Disease Risk Factor Management in Rheumatoid Arthritis Compared to Matched Nonrheumatoid Arthritis in a US Managed Care Setting.
An J; Cheetham TC; Reynolds K; Alemao E; Kawabata H; Liao KP; Solomon DH
Arthritis Care Res (Hoboken); 2016 May; 68(5):629-37. PubMed ID: 26414069
[TBL] [Abstract][Full Text] [Related]
24. Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
Eriksson JK; Johansson K; Askling J; Neovius M
Ann Rheum Dis; 2015 Apr; 74(4):648-54. PubMed ID: 24323395
[TBL] [Abstract][Full Text] [Related]
25. Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure.
Cross MJ; March LM; Lapsley HM; Byrne E; Brooks PM
Rheumatology (Oxford); 2006 Jan; 45(1):92-6. PubMed ID: 16287930
[TBL] [Abstract][Full Text] [Related]
26. Projected Burden of Osteoarthritis and Rheumatoid Arthritis in Australia: A Population-Level Analysis.
Ackerman IN; Pratt C; Gorelik A; Liew D
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):877-883. PubMed ID: 28898565
[TBL] [Abstract][Full Text] [Related]
27. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review.
Rothfuss J; Mau W; Zeidler H; Brenner MH
Semin Arthritis Rheum; 1997 Apr; 26(5):771-9. PubMed ID: 9144852
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
29. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
30. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
31. Health care costs attributable to the treatment of rheumatoid arthritis.
Sørensen J
Scand J Rheumatol; 2004; 33(6):399-404. PubMed ID: 15794199
[TBL] [Abstract][Full Text] [Related]
32. Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis.
Andrews G; Simonella L; Lapsley H; Sanderson K; March L
J Rheumatol; 2006 Apr; 33(4):671-80. PubMed ID: 16541479
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis.
Osiri M; Sattayasomboon Y
Joint Bone Spine; 2013 Dec; 80(6):608-12. PubMed ID: 23827409
[TBL] [Abstract][Full Text] [Related]
34. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis.
Ethgen O; Kahler KH; Kong SX; Reginster JY; Wolfe F
J Rheumatol; 2002 Jun; 29(6):1147-55. PubMed ID: 12064827
[TBL] [Abstract][Full Text] [Related]
35. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
36. Resource utilization and the cost of rheumatoid arthritis in Brazil.
Chermont GC; Kowalski SC; Ciconelli RM; Ferraz MB
Clin Exp Rheumatol; 2008; 26(1):24-31. PubMed ID: 18328143
[TBL] [Abstract][Full Text] [Related]
37. A cost density analysis of benign prostatic hyperplasia.
Lanes SF; Sulsky S; Walker AM; Isen J; Grier CE; Lewis BE; Dreyer NA
Clin Ther; 1996; 18(5):993-1004. PubMed ID: 8930437
[TBL] [Abstract][Full Text] [Related]
38. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
39. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project).
Hallert E; Husberg M; Jonsson D; Skogh T
Rheumatology (Oxford); 2004 Nov; 43(11):1374-82. PubMed ID: 15280570
[TBL] [Abstract][Full Text] [Related]
40. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
Eloubeidi MA; Homan RK; Martz MD; Theobald KE; Provenzale D
Am J Gastroenterol; 1999 Aug; 94(8):2033-6. PubMed ID: 10445524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
